"The health reforms passed by the German Parliament send a concerning signal about how Germany values its role as a leader in pharmaceutical innovation and the significant benefits it enjoys from a thriving Industry.

Deprioritising investment in innovative medicines risks undermining Germany's long-term competitiveness, economic resilience and health security.

To invest in R&D, manufacturing and clinical trials, companies require sustainable reimbursement conditions, predictable prices, internationally competitive framework conditions and an innovation-friendly ecosystem – all of which is increasingly found outside of Europe, specifically in the US and China.

It is also of concern that these policy decisions fail to take into account the introduction of US trade and pricing policies, which are highly likely to exacerbate this difficult situation. The legislation worsens the economic conditions for innovative medicines at a time when Germany should be strengthening its attractiveness for investment, research and production."

Nathalie Moll, Director General, EFPIA